COMMUNITY OUTREACH AND ENGAGEMENT (COE) MD Anderson exists to ??eliminate cancer in Texas, the nation, and the world.? It achieves this mission by operating in four integrated domains ? research, clinical care, education, and prevention/control. Based upon its state charter, state support, patient population, and its primary commitment to improving the health of Texans, the institution defines the state of Texas as its primary catchment area. The Community Outreach and Engagement (COE) component highlights the institution's key resources, relationships, and evidence- based actions taken in priority areas to reduce Texans' cancer burden and associated risk factors. The second most populous state in the country (28.3M residents), Texas is highly diverse and has the greatest number of uninsured residents in the nation. Catchment area priorities include: tobacco use, obesity, ultraviolet radiation, rising rates of hepatocellular cancer (HCC), delivery of HPV vaccination, and equitable delivery of screening services for cervical and colorectal (CRC) cancer. MD Anderson's capacity to advance the health of Texans is sustained through key investments in resources, such as implementation expertise to achieve population level impact through the Cancer Prevention & Control Platform (CPCP), and research infrastructure to advance community informed community based studies through the Center for Community-Engaged Translational Research (CCETR). By activating its network of diverse relationships, including those with educational systems, as well as community and faith-based organizations, MD Anderson amplifies its reach and impact beyond its walls, enabling MD Anderson's connection to and partnership with the community. MD Anderson views research and control actions as complementary activities that inform each other to perpetuate a virtuous cycle to address the needs of Texans. To address identified priorities, MD Anderson leads an array of initiatives dedicated to advancing research and community engagement as well as evidence-based actions to improve public policy, professional and public education (knowledge dissemination), and community-oriented service delivery beyond its direct delivery of patient care services. These efforts are stewarded through engagement of a broad group of CCSG Research Program members and staff working collaboratively across multiple offices, community-based organizations, and clinical partners.
The aims of the COE component are:
Aim 1 : To assess and monitor catchment area rates and trends as well as emerging evidence-based practices in order to identify cancer-related needs and opportunities to address them.
Aim 2 : To plan and prioritize research and control actions to commit MD Anderson's resources (infrastructure and faculty expertise) and relationships and engage communities and partners.
Aim 3 : To implement and evaluate evidence-based actions in policy, public and professional education, and services to increase the use and impact of interventions that reduce the burden of cancer and associated risk factors at the population level and improve outcomes in Texas and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997837
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Takahashi, Nobuaki; Chen, Hsing-Yu; Harris, Isaac S et al. (2018) Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003.e7
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507

Showing the most recent 10 out of 12418 publications